Pnc Financial Services Group, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
Pnc Financial Services Group, Inc.
- $156 Billion
- Q3 2024
A detailed history of Pnc Financial Services Group, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 2,520 shares of CRNX stock, worth $137,894. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,520
Previous 197
1179.19%
Holding current value
$137,894
Previous $8,000
1500.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CRNX
# of Institutions
241Shares Held
79.6MCall Options Held
23.3KPut Options Held
44.3K-
Vanguard Group Inc Valley Forge, PA6.29MShares$344 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$341 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL5.89MShares$322 Million2.95% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.94MShares$271 Million0.03% of portfolio
-
Wellington Management Group LLP Boston, MA4.46MShares$244 Million0.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.94B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...